Discover 1 curated intelligence briefings related to this specific topic.
The shift toward in vivo CAR T and AAV gene therapies is fundamentally altering the economics of medicine. By eliminating the need to extract and modify cells outside the body, the industry is effectively pharmaceuticalizing gene therapy, though regulatory hurdles and clinical process inefficiencies still threaten the pace of adoption.
